Effect of nitric oxide synthase (NOS) activity on Lenvatinib for unresectable hepatocellular carcinoma

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1030210283

Enrollment

100

Registered

2021-08-27

Start date

2021-08-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Unresectable hepatocellular carcinoma Hepatocellular Carcinomas

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with hepatocellular carcinoma who received lenvatinib between October 1, 2018 and September 30, 2020. Patients enrolled in the "Multicenter Study of Factors Contributing to the Efficacy and Survival of Lenvatinib in Hepatocellular Carcinoma". Patients who have arbitrarily stored serum before and after treatment.

Exclusion criteria

Exclusion criteria: Patients who are considered unsuitable for participation in this study by the principal investigator and sub-investigators

Design outcomes

Primary

Measure	Time frame
Comparison of NOS activity at the time of initial administration and after administration in patients with hepatocellular carcinoma treated with lenvatinib	—

Secondary

Measure	Time frame
Effect of NOS activity at first dose on response rate, overall survival, progression-free survival, Time To Progression, Time to treatment failure, and incidence of adverse effects after lenvatinib treatment	—

Contacts

Public ContactHaruki Uojima

Kitasato University

kiruha@kitasato-u.ac.jp+81-42-778-8111

Outcome results